US2019142845A1PendingUtilityA1

Anticonvulsant activity of steroids

Assignee: UNIV CALIFORNIAPriority: Nov 30, 2012Filed: Jan 7, 2019Published: May 16, 2019
Est. expiryNov 30, 2032(~6.3 yrs left)· nominal 20-yr term from priority
A61P 25/32A61P 25/08A61P 25/24A61P 25/34A61P 25/28A61P 25/22A61P 25/00A61K 31/573A61K 9/08A61K 31/56A61K 9/0019A61K 31/57A61K 47/40
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to methods of preventing, inhibiting, delaying, and/or mitigating seizures by administration of a steroid, e.g., a neurosteroid, e.g., allopregnanolone.

Claims

exact text as granted — not AI-modified
1 .- 21 . (canceled) 
     
     
         22 . A composition comprising or consisting essentially of a steroid and a cyclodextrin. 
     
     
         23 . The composition of  claim 22 , wherein the steroid is a neurosteroid. 
     
     
         24 . The composition of  claim 23 , wherein the neurosteroid is selected from the group consisting of allopregnanolone, allotetrahydrodeoxycorticosterone, ganaxolone, alphaxolone, alphadolone, hydroxydione, minaxolone, and Althesin. 
     
     
         25 . The composition of any one of  claims 22  to  24 , wherein the steroid is allopregnanolone. 
     
     
         26 . The composition of any one of  claims 22  to  25 , wherein the cyclodextrin is hydroxypropyl-beta-cyclodextrin, sulfobutylether-beta-cyclodextrin sodium salt, or a mixture thereof. 
     
     
         27 . The composition of any one of  claims 22  to  26 , wherein the composition is formulated for intramuscular (i.m.), subcutaneous (s.c.) or intravenous (i.v.) administration. 
     
     
         28 . The composition of any one of  claims 22  to  27 , wherein the composition comprises allopregnanolone and sulfobutylether-beta-cyclodextrin sodium salt.

Join the waitlist — get patent alerts

Track US2019142845A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.